Full Press Release Details
Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
DIEGO, CA - November 17, 2025 - Ensysce Biosciences, Inc. (NASDAQ: ENSC)("Ensysce" or the
"Company"), pioneering novel solutions for severe pain with built-in abuse and overdose protection, today announced the
closing of a $4 million convertible preferred stock financing, with upside to potentially $16 million of additional funding
available through future tranches over the next 24 months.
capital will accelerate the Phase 3 clinical program for PF614, Ensysce's flagship analgesic candidate, while supporting general
corporate initiatives. The initial $4 million tranche includes a fixed conversion price of $2.50 per share, with an alternate conversion
price based upon average common stock prices prior to conversion. The financing includes 50% warrant coverage on each takedown, exercisable
at the fixed conversion price for five years, subject to adjustment.
| $4 Million Closed Now, $16 Million Available: Providing funding flexibility to advance critical programs. | ||
| Phase 3 Acceleration: PF614 clinical trials moving toward market readiness within 18-24 months. | ||
| Investor Confidence: Current backers continue to support Ensysce's mission-driven innovation. |
Kirkpatrick, CEO of Ensysce Biosciences, stated, "This financing demonstrates strong investor confidence in Ensysce's vision:
safe, effective analgesics that re-invent pain management. With PF614 on track for Phase 3 completion in the next 18 months and federal
grant support for our MPAR program, we are moving closer to delivering transformative treatments for patients in urgent need."
Biosciences is a clinical stage company with a goal of disrupting the analgesic landscape by introducing a new class of highly novel
opioids for the treatment of severe pain. Leveraging its Trypsin-Activated Abuse Protection (TAAPTM) and Multi-Pill Abuse
Resistance (MPAR ) platforms, the Company is developing unique, tamper-proof treatment options for pain that minimize
the risk of both drug abuse and overdose. Ensysce's products are anticipated to provide safer options to treat patients suffering
from severe pain and assist in preventing deaths caused by medication abuse. Ensysce's pipeline is backed by a robust global intellectual
property portfolio, offering hope to patients and providers confronting the challenges of pain management. Learn more at www.ensysce.com.
contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the
safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting
the foregoing, the use of words such as "may," "intends," "can," "might," "will,"
"expect," "plan," "possible," "believe" and other similar expressions are intended to
identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that
the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays
in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking
statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are
inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially
from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among
others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies
and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's
product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations,
including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners'
ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of
material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports
on Form 8-K, available free of charge at the SEC's website at www.sec.gov. Any forward-looking statement speaks only as of the
date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a
result of new information, future events or otherwise, except as required under applicable law.
Biosciences Company Contact:
Lynn Kirkpatrick, Ph.D.
Biosciences Investor Relations Contact:
Ensysce Biosciences Inc.